Guardant Health (GH)
(Real Time Quote from BATS)
$18.95 USD
+0.37 (1.99%)
Updated May 3, 2024 12:46 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GH 18.95 +0.37(1.99%)
Will GH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
Other News for GH
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors
Guardant Health price target lowered by $15 at Canaccord, here's why
ClearBridge All Cap Growth Strategy Q1 2024 Commentary
Guardant Health assumed with a Buy at Craig-Hallum
Key Takeaways From Guardant Health Analyst Ratings